Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Biological therapy of rheumatoid arthritis: is it a real prediction of efficacy?

[Internal diseases]
Pavel Koroy; Vijaya Sarithala; Alexandr Yagoda;

Relationship of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), plateletendothelial cell adhesion molecule-1 (PECAM-1), E-, P- and L-selectins blood levels with results of three-monthly combination treatment by biological agents and methotrexate was studied in 35 patients with rheumatoid arthritis (29 women, 6 men) at age from 40 to 66 with previous noneffective methotrexate treatment. Tocilizumab was applied in 20 patients, in 15 cases etanercept was used. The moderate effect of treatment was observed in 74.3 % of cases, remission or low activity of rheumatoid arthritis were reached in 22.9 % of patients, 9 patients were non-responders. Increase of blood concentration of all immunoglobulins superfamily molecules and of P-selectin was observed in rheumatoid arthritis. After 3 months of therapy decrease in VCAM-1, PECAM-1 blood levels and normalization of ICAM-1, P-selectin values were observed, especially in cases of effective treatment, in non-responders there was reduction only of ICAM-1 levels. The favorable response to treatment was associated with high initial levels of ICAM-1, РЕСАМ-1 and low levels of P-selectin in blood that opens new possibilities of use of adhesion molecules in prediction of successful therapy of RA.


1. Smolen J. S., Landewé R., Bijlsma J., Burmester G., Chatzidionysiou K. [et al.] EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017;76(6):960-977. https://doi.org/10.1136/annrheumdis-2016-210715
2. Li N., Betts K. A., Messali A. J., Skup M., Garg V. Real-world effectiveness of biologic disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis after etanercept discontinuation in the United Kingdom, France, and Germany. Clin. Ther. 2017;39(8):1618-1627. https://doi.org/10.1016/j.clinthera.2017.06.009
3. Kotak S., Mardekian J., Horowicz-Mehler N., Shah A., Burgess A. [et al.] Impact of etanercept therapy on disease activity and health-related quality of life in moderate rheumatoid arthritis patients population from a National British
Observational Cohort. Value Health. 2015;18(6):817-823. https://doi.org/10.1016/j.jval.2015.05.005
4. Kihara M., Davies R., Kearsley-Fleet L., K. Watson D., Lunt M. [et al.] Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin. Rheumatol. 2017;36(2):241-250.
5. Gremese E., Carletto A., Padovan M., Atzeni F., Raffeiner B. [et al.] Obesity and reduction of the response rate to anti-tumor necrosis factor-α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res. 2013;65(1):94-100. https://doi.org/10.1002/acr.21768
6. Klimek E., Skalska A., Kwaśny-Krochin B., Surdacki A., Sulicka J. [et al.] Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm. 2014;2014:681635. https://doi.org/10.1155/2014/681635
7. Koroy P. V., Sarithala V. D., Yagoda A. V. Soluble molecules of immunoglobulins superfamily in rheumatoid arthritis. Medical news of North Caucasus. 2017;12(3):256-260. https://doi.org/10.14300/mnnc.2017.12092
8. Södergren A., Karp K., Boman K., Eriksson C., Lundström E. [et al.] Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res. Ther.2010;12(4):R158. https://doi.org/10.1186/ar3116
9. Yagoda А. V., Sarithala V. J., Koroy P. V. Anemia in rheumatoid arthritis: correlation with hepcidin and adhesion molecules. Meditsinskii vestnik Severnogo Kavkaza – Medical News of North Caucasus. 2018;13(2):338-342. (In Russ.). https://doi.org10.14300/mnnc.2018.13044
10. Sarithala V. J., Koroy P., Yagoda A. Variations in levels of intercellular adhesion molecule-1 with disease course, in rheumatoid arthritis patients. J. Clin. Diagnostic Res. 2018;12(9):18-21. https://doi.org/10.7860/JCDR/2018/35302.12044
11. Gonzalez-Gay M. A., De Matias J. M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A. [et al.] Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2006;24(1):83-86.
12. Gonzales-Gay M. A., Garcia-Unzueta M. T., de Matias J. M., Gonzalez-Juanatey C., Garcia-Porrua C. [et al.] Influence of anti-TNF-a infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2006; 24(4):373-379.
13. Klimiuk P. A., Sierakowski S., Domyslawska I., Chwiecko J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand. J. Rheumatol. 2009;38(6):439- 444. https://doi.org/10.3109/03009740903079321
14. Dessein P. H., Joffe B. I., Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther. 2005;7(3):R634. https://doi.org/10.1186/ar1717
15. Klimiuk P. A., Fiedorczyk M., Sierakowski S., Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM- 1, and sE-selectin) in patients with early rheumatoid arthritis. Scand. J. Rheumatol. 2007;36(5):345-350. https://doi.org/10.1080/03009740701406460
16. Gonzalez-Juanatey C., Llorca J., Sanchez-Andrade A., Garcia-Porrua C., Martin J. [et al.] Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 2006;24(3):309-312.
17. Oranskiy S. P., Yeliseyeva L. N. Serum concentration of immune, endocrine and endothelial biomarkers in patients with rheumatoid arthritis associated with different variants of metabolic status treated with infliximab. Medical news of North Caucasus. 2016;11(2):139-142.https://doi.org/10.14300/mnnc.2016.11019
18. Shu Q., Amin M. A., Ruth J. H., Campbell P. L., Koch A. E. Suppression of endothelial cell activity by inhibition of TNF alpha. Arthritis Res. Ther. 2012;14(2):R88. https://doi.org/10.1186/ar3812
19. Komarova E. B., Rebrov B. A., Knyazeva A. K. An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis. Sovremennaya Revmatologiya – Modern Rheumatology Journal. 2017;11(3):72-76. (In Russ.). https://doi.org/10/14412/1996-7012-2017-3-72-76
20. Nozaki K., Hikiami H., Goto H., Nakagawa T., Shibahara N. [et al.] Keishibukuryogan (Gui-Zhi-Fu-Ling-Wan), a Kampo Formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis. eCAM. 2006;3(3):359-364. https://doi.org/10.1093/ecam/nel025
21. Elshabrawy H. A., Chen Z., Volin M. V., Ravella S., Virupannavar S. [et al.] The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015;18(4):433-448. https://doi.org/10.1007/s10456-015-9477-2
22. Hodkinson B., K. Magomero R., Tikly M. Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach. Ther. Adv. Musculoskelet. Dis. 2016;8(5):172-179. https://doi.org/10.1177/1759720X16664324
23. Tanaka H., Kanazawa M., Kawakami T. Efficacy and safety of tocilizumab therapy in rheumatoid arthritis: prevalence and predictive factors of sustained remission. Ann. Rheuma. Dis. 2013;72(3):453.
24. Canhão H., Rodrigues A. M., Mourão A. F., Martins F., Santos M. J. [et al.] Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology. 2012;51(11):2020-2026. https://doi.org/10.1093/rheumatology/kes184
25. Wevers-de Boer K., Visser K., Heimans L., Ronday H. K., Molenaar E. [et al.] Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann. Rheum. Dis. 2012;71(9):1472-1477.

Keywords: rheumatoid arthritis, immunoglobulins superfamily molecules, selectins, biological therapy, prediction of efficacy

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy